Biomotion Sciences Ordinary Shares (SLXN) Financials

$0.85

south_east
-$0.05 (-5.06%)
Day's range
$0.83
Day's range
$0.91
$0$0-$1M-$1M-$2M-$2M-$3M-$3M-$4M-$4M-$5M-$5MEarning20222022202320235%5%4%4%3%3%2%2%1%1%0%0%Profit Margin
Profit Margin
Revenue
Earnings

SLXN Income statement / Annual

Last year (2023), Silexion Therapeutics LTD's total revenue was $0.00, and the percentage change from the previous year is not available. In 2023, Silexion Therapeutics LTD's net income was -$4.94 M. See Silexion Therapeutics LTD,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022
Period Ended 12/31/2023 12/31/2022
Operating Revenue $0.00 $0.00
Cost of Revenue $0.00 $0.00
Gross Profit $0.00 $0.00
Gross Profit Ratio 0 0
Research and Development Expenses $3.71 M $3.23 M
General & Administrative Expenses $928,000.00 $577,000.00
Selling & Marketing Expenses $0.00 $0.00
Selling, General & Administrative Expenses $928,000.00 $577,000.00
Other Expenses $45,000.00 $57,000.00
Operating Expenses $4.68 M $3.86 M
Cost And Expenses $4.68 M $3.86 M
Interest Income $153,000.00 $114,000.00
Interest Expense $9,000.00 $85,000.00
Depreciation & Amortization $45,000.00 $57,000.00
EBITDA -$4.64 M -$3.80 M
EBITDA Ratio 0 0
Operating Income Ratio 0 0
Total Other Income/Expenses Net -$395,000.00 $396,000.00
Income Before Tax -$5.08 M -$3.46 M
Income Before Tax Ratio 0 0
Income Tax Expense $32,000.00 $24,000.00
Net Income -$4.94 M -$3.22 M
Net Income Ratio 0 0
EPS -0.61 -0.39
EPS Diluted -0.61 -0.39
Weighted Average Shares Out $8.15 M $8.15 M
Weighted Average Shares Out Diluted $8.15 M $8.15 M
Link